NT5E and glioblastoma: Recently, we demonstrated the potential for CD73 blockade using either specific siRNA sequences or a pharmacological inhibitor in controlling glioblastoma progression in vitro and in an orthotopic immunocompetent in vivo model using Wistar rats.